[go: up one dir, main page]

EA200901212A1 - 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний - Google Patents

3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний

Info

Publication number
EA200901212A1
EA200901212A1 EA200901212A EA200901212A EA200901212A1 EA 200901212 A1 EA200901212 A1 EA 200901212A1 EA 200901212 A EA200901212 A EA 200901212A EA 200901212 A EA200901212 A EA 200901212A EA 200901212 A1 EA200901212 A1 EA 200901212A1
Authority
EA
Eurasian Patent Office
Prior art keywords
proliferative diseases
imidazolylindoles
treatment
intended
variants
Prior art date
Application number
EA200901212A
Other languages
English (en)
Inventor
Андреас Бёттхер
Николе Бушманн
Паскаль Фюре
Жан-Марк Гроэлль
Йёрг Каллен
Ивонна Хергових-Лиштван
Кейичи Масуя
Лоренц Майр
Андреа Фаупель
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38328915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200901212(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA200901212A1 publication Critical patent/EA200901212A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

В настоящем изобретении предлагаются соединения, относящиеся к производным 3-гетероциклилиндолила, способным ингибировать взаимодействие между р53, или его вариантами, и MDM2 и/или MDM4, или их вариантами, соответственно, и указанные соединения характеризуются формулой (I), где R, R, R, R, R, Y и Y имеют значения, определенные в описании изобретения. Благодаря их активности, соединения можно использовать для лечения различных заболеваний и нарушений, оппосредованных активностью MDM2 и/или MDM4, или их вариантами, таких как воспалительные заболевания или пролиферативные заболевания или для защиты клеток.
EA200901212A 2007-03-29 2008-03-27 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний EA200901212A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07105269 2007-03-29
PCT/EP2008/053667 WO2008119741A2 (en) 2007-03-29 2008-03-27 3-imidazolyl-indoles for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
EA200901212A1 true EA200901212A1 (ru) 2010-04-30

Family

ID=38328915

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901212A EA200901212A1 (ru) 2007-03-29 2008-03-27 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний

Country Status (27)

Country Link
US (1) US8053457B2 (ru)
EP (1) EP2142535A2 (ru)
JP (1) JP2010522723A (ru)
KR (1) KR20090122403A (ru)
CN (1) CN101679382A (ru)
AR (1) AR065860A1 (ru)
AU (1) AU2008234954B9 (ru)
BR (1) BRPI0810082A2 (ru)
CA (1) CA2682483A1 (ru)
CL (1) CL2008000899A1 (ru)
CR (1) CR11019A (ru)
DO (1) DOP2009000229A (ru)
EA (1) EA200901212A1 (ru)
EC (1) ECSP099660A (ru)
GT (1) GT200900256A (ru)
IL (1) IL200862A0 (ru)
MA (1) MA31260B1 (ru)
MX (1) MX2009010413A (ru)
NI (1) NI200900177A (ru)
PA (1) PA8774001A1 (ru)
PE (1) PE20081897A1 (ru)
SM (1) SMP200900085B (ru)
TN (1) TN2009000388A1 (ru)
TW (1) TW200843746A (ru)
UY (1) UY30987A1 (ru)
WO (1) WO2008119741A2 (ru)
ZA (1) ZA200906210B (ru)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007235578B2 (en) * 2006-04-07 2011-07-14 Janssen Pharmaceutica N.V. Indoles and benzoimidazoles as modulators of the histamine H4 receptor
AR070398A1 (es) * 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
WO2009158375A1 (en) * 2008-06-25 2009-12-30 Abbott Laboratories Aza-cylic indole- 2 -carboxamides and methods of use thereof
EP3269395A1 (en) 2008-11-07 2018-01-17 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
MX2011007598A (es) 2009-01-16 2011-08-08 Daiichi Sankyo Co Ltd Derivados de imidazotiazol que tienen estructura de anillo de prolina.
JP2012102017A (ja) * 2009-03-03 2012-05-31 Astellas Pharma Inc インドール化合物
EP2419408A4 (en) * 2009-04-16 2012-09-05 Msd Kk INDOLE SUBSTITUTED DERIVATIVE IN POSITION 3 BY ARYL OR HETEROARYLE
CA2780547C (en) 2009-11-12 2015-02-03 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
WO2011106650A2 (en) * 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
EP2614051A4 (en) * 2010-09-08 2014-01-29 Univ Pittsburgh P53-MDM2 ANTAGONISTS
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
TWI535723B (zh) 2010-11-12 2016-06-01 密西根大學董事會 螺－吲哚酮ｍｄｍ２拮抗劑
US20120202794A1 (en) * 2011-01-24 2012-08-09 Pharmasset, Inc. Compounds
PH12013501875A1 (en) 2011-03-10 2016-06-29 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivative
EP2691443B1 (en) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Conjugated lipomers and uses thereof
CN102702066A (zh) * 2011-03-28 2012-10-03 苏州百灵威超精细材料有限公司 一种用于合成抗癌和减肥药物中间体6-氯-5-氟吲哚的制备新方法
MX346375B (es) 2011-05-11 2017-03-16 Univ Michigan Regents Antagonistas de espiro-oxindol de mdm2.
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2012176123A1 (en) * 2011-06-22 2012-12-27 Novartis Ag 3 - imidazolyl- indoles for the treatment of proliferative diseases
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
AU2012352177A1 (en) 2011-12-13 2014-07-10 Buck Institute For Research On Aging Methods for improving medical therapies
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
CA2939121C (en) 2014-01-28 2020-11-24 Mayo Foundation For Medical Education And Research Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
EP3708170A1 (en) 2014-05-05 2020-09-16 BioVentures, LLC Compositions and methods for inhibiting antiapoptotic bcl-2 proteins as anti-aging agents
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
JP6503386B2 (ja) 2014-07-03 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
CA2955972A1 (en) 2014-07-22 2016-01-28 Bioventures, Llc. Compositions and methods for selectively depleting senescent cells
KR20170098860A (ko) 2014-12-26 2017-08-30 다우 글로벌 테크놀로지스 엘엘씨 유기 화합물 및 유기 화합물을 포함하는 유기 층을 포함하는 전자 디바이스
CN107427501B (zh) 2015-02-20 2023-12-01 第一三共株式会社 通过联合使用治疗癌症的方法
CA2982435C (en) 2015-04-13 2020-05-26 Daiichi Sankyo Company, Limited Treatment method by combined use of mdm2 inhibitor and btk inhibitor
SG10201908685QA (en) * 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6602470B2 (ja) 2015-10-09 2019-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｄｍ２−ｐ５３阻害薬としてのスピロ［３ｈ−インドール−３，２‘−ピロリジン］−２（１ｈ）−オン化合物及び誘導体
CN109415336B (zh) 2016-04-06 2023-08-29 密执安大学评议会 Mdm2蛋白质降解剂
JP7001614B2 (ja) 2016-04-06 2022-02-03 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン リガンド依存性の標的タンパク質分解のための単官能性中間体
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CN105906610B (zh) * 2016-05-24 2018-10-23 绍兴文理学院 一种3-（4-苯基-1h-咪唑-5-基）-1h-吲哚衍生物及其制备方法和应用
DK3272745T3 (da) 2016-07-21 2019-09-02 Inst Farmakologii Polskiej Akademii Nauk Imidazolylsubstituerede indolderivater, der binder 5-ht7-serotoninreceptor, og farmaceutiske sammensætninger deraf
KR20190068544A (ko) 2016-10-17 2019-06-18 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 dna 메틸트랜스페라아제 저해제의 병용 치료법
CN110225911B (zh) 2016-11-28 2022-04-05 豪夫迈·罗氏有限公司 噁二唑酮瞬时受体电位通道抑制剂
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
JP7178357B2 (ja) 2017-03-07 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
MX2019011945A (es) 2017-04-05 2019-11-28 Boehringer Ingelheim Int Terapia de combinacion contra cancer.
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN111163774A (zh) * 2017-05-26 2020-05-15 罗格斯新泽西州立大学 细菌外排泵抑制剂
US12118414B2 (en) 2018-01-22 2024-10-15 Bioventures, Llc BCL-2 proteins degraders for cancer treatment
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
EP3931188B1 (en) * 2019-02-26 2023-08-30 Boehringer Ingelheim International GmbH New isoindolinone substituted indoles and derivatives as ras inhibitors
US12186401B2 (en) 2019-03-01 2025-01-07 Ontario Institute for Cancer Research (OICR) and Sinai Health System Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses
WO2022137085A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Indole derivatives useful in treating conditions associated with cgas
US20220306609A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19948417A1 (de) * 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
JP2002114780A (ja) * 2000-10-11 2002-04-16 Taisho Pharmaceut Co Ltd ４−（３−インドリル）イミダゾール誘導体
EP1856123B1 (en) 2005-02-22 2016-02-17 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives

Also Published As

Publication number Publication date
PA8774001A1 (es) 2008-11-19
GT200900256A (es) 2010-03-15
ZA200906210B (en) 2010-05-26
ECSP099660A (es) 2009-10-30
IL200862A0 (en) 2010-05-17
CL2008000899A1 (es) 2009-02-20
WO2008119741A3 (en) 2008-12-04
SMAP200900085A (it) 2010-01-19
JP2010522723A (ja) 2010-07-08
MX2009010413A (es) 2009-10-20
KR20090122403A (ko) 2009-11-27
SMP200900085B (it) 2010-11-12
PE20081897A1 (es) 2009-02-09
CA2682483A1 (en) 2008-10-09
AU2008234954B2 (en) 2011-10-27
MA31260B1 (fr) 2010-03-01
CN101679382A (zh) 2010-03-24
BRPI0810082A2 (pt) 2014-10-21
NI200900177A (es) 2010-09-09
TW200843746A (en) 2008-11-16
EP2142535A2 (en) 2010-01-13
UY30987A1 (es) 2008-10-31
US8053457B2 (en) 2011-11-08
CR11019A (es) 2009-10-20
WO2008119741A2 (en) 2008-10-09
TN2009000388A1 (en) 2010-12-31
AU2008234954B9 (en) 2012-02-02
US20100125064A1 (en) 2010-05-20
AR065860A1 (es) 2009-07-08
AU2008234954A1 (en) 2008-10-09
DOP2009000229A (es) 2009-10-31

Similar Documents

Publication Publication Date Title
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
EA201500769A1 (ru) Ингибиторы е1 активирующих ферментов
EA201071089A1 (ru) Производные хиназолина как модуляторы raf-киназы и способы их применения
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201001331A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR
EA200900285A1 (ru) Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA201170349A1 (ru) Модуляторы mif
EA201201665A1 (ru) Новые соединения
EA201170521A1 (ru) Новые соединения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MA32811B1 (fr) Nouveaux composés
EA201170052A1 (ru) Производные тиофена или тиазола и их применение как ингибиторов pi3k
EA201100564A1 (ru) Антипролиферативные соединения
EA201170963A1 (ru) Ингибиторы поли(адф-рибозо)полимеразы (parp)
EA201071320A1 (ru) Активаторы глюкокиназы
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EP2571876A4 (en) 7-CHAIN SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL-PEPTIDASE IV FOR THE TREATMENT OF DIABETES
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
EA201070158A1 (ru) Сульфонамиды в качестве trpm8 модуляторов